Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 5, 2013, Pages 370-379

  Vaklavas, Christos ^a   Meredith, Ruby F ^a   Shen, Sui ^a   Knox, Susan J ^b   Micallef, Ivana N ^c   Shah, Jatin J ^d   Lobuglio, Albert F ^a   Forero Torres, Andres ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

90Yttrium ibritumomab tiuxetan; immunotherapeutic approaches; lymphoma and other lymphoproliferative conditions; radioimmunotherapy; rituximab

Indexed keywords

ANTIBIOTIC AGENT; CD20 ANTIGEN; GROWTH FACTOR; IBRITUMOMAB TIUXETAN; RITUXIMAB;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE CLEARANCE; DISEASE SEVERITY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINUSITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 84878844262     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1387     Document Type: Article

References (31)

1. Ansell SM, Armitage J. Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc 2005;80:1087.
2. Zinzani PL, d'Amore F, Bombardieri E, et al. Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer 2008;44:366.
3. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol 2011;29:1827.
4. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725.
6. Witzig TE. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2001;48 Suppl 1:S91.
7. Khan KD, Emmanouilides C, Benson DM, Jr., et al. A phase 2 study of rituximab in combination with recombinant interleukin- 2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:7046.
8. Ansell SM, Geyer SM, Maurer MJ, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 2006;12:6056.
9. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non- Hodgkin's lymphomas. J Clin Oncol 2005;23:2240.
10. Rossi EA, Goldenberg DM, Cardillo TM, et al. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864.
11. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000;27:62.
12. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with lowgrade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565.
13. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
14. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 2002;99:4336.
15. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262.
16. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20( + ) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793.
17. Govindan SV; Goldenberg DM. New antibody conjugates in cancer therapy. ScientificWorldJournal 2010;10:2070.
18. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti- CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457.
19. Shen S, Forero A, Meredith RF, et al. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med 2010;51:150.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
22. National Cancer Institute, Cancer Therapy Evaluation Program. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm, 1999; Vol. 2012 (last accessed on Jan 13, 2013).
23. IBM. http://www-01.ibm.com/software/analytics/spss/ (last accessed on Jan 13, 2013).
24. National Cancer Institute. Cancer Therapy Evaluation Program. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.511. pdf, 2010. (last accessed on Jan 13, 2013).
25. Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113:1412.
26. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263.
27. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995.
28. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851.
29. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825.
30. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804.
31. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258.